Biotech Company Focused on the Development and Commercialisation of Novel IVD Tests [Interview][Transcript]

Guest: Matthew Hoskin

Presenter: Henry Acosta

Guest Bio: Matthew has a wealth of experience in leading and growing medtech companies in both the local and international markets. His keen interest in cancer diagnostics has seen him work with a number of multi-national companies specialising in antibodies and reagent detection systems, automated IHC / ICC stainers, tissue processors, pathology capital equipment as well as consumables and oncology pharmaceuticals.

With over 20 years’ experience leading businesses in the biotech and healthcare sectors, including Siemens Medical, Leica Biosystems and Hospira, Matthew played a key role in driving the growth at Vision Biosystems which became one of Australia’s most profitable biotechs and ultimately sold for AUD $800 million.

Segment Overview: In today’s Health Supplier Segment, we are joined by Sienna Cancer Diagnostics CEO Matthew Hoskin here to share information about their company’s focused on the development and commercialisation of novel in vitro diagnostic (IVD) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. At Sienna, Matthew’s efforts are focused on company growth and achieving profitability through the delivery of high quality products that address unmet market needs, and delivering them with commercial excellence. His extensive experience in driving revenue and profit whilst ensuring operational excellence in all aspects of the business is invaluable to Sienna in its pursuit of global diagnostics success.

Transcript – TBU

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.